Keating / Dicke / Gorin Regenerative and Cell Therapy

Clinical Advances
2005
ISBN: 978-3-540-26843-7
Verlag: Springer Berlin Heidelberg
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, Band 11, 180 Seiten

Reihe: Ernst Schering Foundation Symposium Proceedings

This book gives an updated review of the state of the art in regenerative cell therapy in the fields of cardiology, hematology, pediatrics, neurology, orthopedics and infectious diseases. The book emphasizes clinical advances as proof of concept in cell therapy based on the revolutionizing observation that regeneration can occur throughout the body even in highly differentiated organs like the heart and the neuronal system. It provides examples of breakthroughs in the clinical implementation of adult stem cell therapy.

Autoren/Hrsg.

Keating, A.

Dicke, K.

Gorin, N.

Weber, R.

Graf, H.

Inhaltsverzeichnis

1;Preface;5
2;Contents;7
3;List of Editors and Contriiutors;9
3.1;Editors;9
3.2;Coeditors;9
3.3;Contributors;10
4;Problems and Hopes with Cell Therapy: The Case of Muscular Dystrophy;13
4.1;Introduction;13
4.2;Early Attempts with Myoblasts Transplantation;15
4.3;Why Bone Marrow Transplantation ;16
4.4;Multipotent Stem Cells in the Bone Marrow;18
4.5;Stem Cells with a Myogenic Potential from Tissues Other than Bone Marrow;22
4.6;The Cellular Environment of a Dystrophic Muscle;23
4.7;Future Perspectives;26
4.8;References;27
5;Cardiac Myoilasts;33
5.1;Introduction;33
5.2;Basic Assumptions;34
5.3;Skeletal Myoblasts for Cardiac Repair Experimental Studies;35
5.4;Skeletal Myoblasts for Cardiac Repair Clinical Studies;39
5.5;Skeletal Myoblasts for Cardiac Repair Future Directions;41
5.6;References;44
6;Tissue Engineering Stem Cells and Cloning: Current Concepts and Future Trends;47
6.1;Introduction;48
6.2;Tissue Engineering Principles;49
6.3;Stem Cells;51
6.4;Therapeutic Cloning;52
6.5;Biomaterials for Regenerative Medicine;54
6.6;Tissue Engineering of Specific Structures;57
6.7;Cellular Therapies;66
6.8;Conclusions;70
6.9;References;70
7;Bone Marrow Cell Therapy for Genetic Disorders of Bone;80
7.1;Osteogenesis Imperfecta;81
7.2;Overview of Clinical Trials;82
7.3;Bone Marrow Transplantation;84
7.4;Mesenchymal Cell Transplantation;86
7.5;Developmental Outcome;89
7.6;Conclusions;89
7.7;References;90
8;Immune Based Cell Therapy for Acute and Chronic Neurodegenerative Disorders;92
8.1;Immune Based Therapies for CNS Injuries;92
8.2;Spinal Cord Injury and Immune Intervention;94
8.3;Protective Autoimmunity A Physiological Response to CNS Insult;95
8.4;Regulation of Protective Autoimmunity and the Mechanism Underlying It;98
8.5;Dendritic Cells A Therapeutic Immune Cell Based Therapy Linking Adaptive and Innate Immunity;100
8.6;A Therapeutic Vaccine for Neurodegenerative Diseases;101
8.7;Concluding Remarks;102
8.8;References;103
9;Mesenchymal Stem Cells for the Treatment of Hematological Malignancies;108
9.1;Introduction;108
9.2;Mesenchymal Stem Cells in HSCT;109
9.3;Mesenchymal Stem Cells for Bone Marrow Failure;115
9.4;Conclusion;116
9.5;References;116
10;Perspectives in Transfusion Medicine for the Ex Vivo Control of Hematopoiesis;119
10.1;In Vitro Control of the Proliferation and Differentiation of Hematopoietic Stem Cells;119
10.2;Enucleation A Complex and Poorly Understood Phenomenon;122
10.3;In Vivo Fate of the Erythroblast Precursors Produced In Vitro;125
10.4;A Quantitative Challenge for Use in Transfusion;126
10.5;References;128
11;T Cell Therapies for EBV-Associated Malignancies;130
11.1;Introduction;130
11.2;Type Latency Posttransplant Lymphoproliferative Disease;131
11.3;Type Latency Hodgkin s Disease;133
11.4;Improving the Efficacy of Infused CTL;134
11.5;Type Latency Nasopharyngeal Carcinoma;136
11.6;Conclusion;137
11.7;References;137
12;Peptide Vaccination of Myeloid Leukemia;140
12.1;Introduction;140
12.2;Potential Target Antigens;142
12.3;Clinical Trial;147
12.4;Conclusion;148
12.5;References;148
13;Hematopoietic Cell Transplantation after Nonmyeloailative Conditioning;154
13.1;Introduction;155
13.2;GVT Effect;156
13.3;Preclinical Data from a Canine Model;158
13.4;Clinical Application of Nonmyeloablative Conditioning for HCT;165
13.5;Reduced Intensity HCT Results from Other Centers;171
13.6;References;177